Drug Trial Radar · NCT06684743
Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Adults
Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
690,000
Planned (sponsor's estimate)
Start
Nov 18, 2024
Primary completion
May 2028
Study completion Aug 2028
Sponsor
- Lead sponsor
- Tor Biering-SørensenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Pfizer
- First posted
- Nov 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of bivalent RSV prefusion F vaccine (RSV vaccine) in adults. Participants will be randomized 1:1 to either RSV vaccine or no RSV vaccine.
Conditions
- RSV
Interventions
RSV prefusion F protein-based vaccineBiological
For this arm, the RSV prefusion F protein-based vaccine Abrysvo® will be used
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hospitalization for RSV-related respiratory tract diseaseTime frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Center for Translational Cardiology and Pragmatic Randomized Trials Department of Cardiology Copenhagen University Hospital - Herlev and Gentofte
Copenhagen, Denmark
Danske Lægers Vaccinations Service
Søborg, Denmark
General Public Health Directorate of Galician Health Service
Santiago de Compostela, A Coruña, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.